RabAvert Shortage Update: What Patients Need to Know in 2026

If you've been trying to get RabAvert and hitting dead ends, you might be wondering: is this a shortage? The answer is nuanced. RabAvert is not on the FDA's official Drug Shortage list in 2026. But access challenges are very real — and understanding why can help you find what you need.

Current RabAvert Supply Status (2026)

As of 2026, RabAvert is not listed on the FDA Drug Shortage database. Bavarian Nordic — the Danish biotech company that acquired global rights to RabAvert from GSK in 2020 — completed its full manufacturing technology transfer in late 2024. The company reported a 20% increase in Rabipur/RabAvert revenue in 2025, with RabAvert holding approximately 77% of the U.S. market share for human rabies vaccines.

In short: the vaccine is being produced and distributed. The challenge is not production — it's how and where the vaccine is distributed and stocked.

Historical Context: Has RabAvert Been in Shortage Before?

Yes. RabAvert and Imovax (the only two FDA-approved human rabies vaccines in the U.S.) have experienced supply disruptions in the past. The market transition between manufacturers — from Novartis to GSK, and then from GSK to Bavarian Nordic — created periods of reduced availability, particularly in Germany and other European markets. In the U.S., the transition period from GSK to Bavarian Nordic (2020–2024) required regulatory approval of a new manufacturing process, which introduced some supply uncertainty.

These disruptions highlighted how vulnerable the rabies vaccine supply chain can be when there are only two manufacturers for an entire country's supply. By 2025 and into 2026, Bavarian Nordic's completed technology transfer has stabilized supply significantly.

Why Is It Still Hard to Find RabAvert at a Pharmacy?

Even with stable manufacturing, individual patients frequently report difficulty finding RabAvert at their local pharmacy. This is due to several structural factors:

• Not a retail pharmacy item: RabAvert must be administered by a healthcare professional and requires refrigeration, so most retail pharmacies don't stock it.
• Specialized distribution channels: The vaccine flows primarily through hospital, travel clinic, and public health channels — not the same supply chain as retail medications.
• Unpredictable demand: Rabies exposures are difficult to predict, and individual facilities can be caught off guard by sudden demand spikes, especially in areas with active wildlife rabies activity.
• High cost per dose: At $393–$535 per vial, clinics face financial risk stocking large quantities of a vaccine that may expire before use.

Who Is Most Affected by RabAvert Access Challenges?

While any patient can face difficulty finding RabAvert, certain groups are most impacted:

• Travelers seeking pre-exposure prophylaxis (PrEP): Those planning to visit rabies-endemic countries who need a full vaccine series before departure often struggle to schedule multiple doses at a conveniently located provider.
• Patients in rural or underserved areas: Specialty vaccine stocking is concentrated in urban and suburban settings. Rural patients may need to travel significant distances to access RabAvert.
• Uninsured patients: Without insurance, a full post-exposure prophylaxis course can cost $5,000–$10,000 or more including HRIG and provider fees.

Rabies Exposure Situations That Require Immediate Action

A reminder on urgency: if you've had a potential rabies exposure, access challenges do not change the timeline for treatment. You must seek care immediately — do not wait to locate RabAvert at a specific pharmacy. Standard protocol:

1. Wash the wound immediately with soap and water for at least 15 minutes
2. Go to the nearest emergency department right away
3. A healthcare provider will assess the exposure and initiate PEP if warranted — emergency departments are equipped to source and administer both vaccine and HRIG

What to Do If You're Having Trouble Finding RabAvert

For patients having trouble locating RabAvert — whether for PEP follow-up doses or pre-exposure vaccination — here's what to do:

• Use medfinder: Visit medfinder.com and search for RabAvert. medfinder will call pharmacies and clinics near you to find which ones have it available.
• Contact your county public health department: They maintain emergency supplies of rabies vaccine and can help coordinate access.
• Ask about Imovax: Imovax (HDCV) is FDA-approved and interchangeable with RabAvert. If one is unavailable, the other can be used.
• Search travel clinics and infectious disease clinics: These specialty settings routinely stock rabies vaccine.

The Bottom Line for Patients in 2026

RabAvert is not in a formal shortage in 2026, but structural factors in how it's distributed and stocked make it genuinely difficult to find at standard pharmacies. The supply situation is stable and improving. For most patients, the challenge is navigation — knowing where to look. Tools like medfinder and your local public health department are your best allies. For detailed strategies, see: How to Find RabAvert in Stock Near You.